Clinical Trials in Dallas

Showing 3641-3660 of 17,468 trials

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

NCT05383274

Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.

Urethral Stricture

Urotronic Inc.34 participantsStarted Feb 2022

Little Rock, Arkansas, United States • Orlando, Florida, United States • Tampa, Florida, United States +6 more locations

COMPLETEDPhase 1< 1 mile

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT04169711

The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).

Clear Cell Renal Cell Carcinoma

Arrowhead Pharmaceuticals26 participantsStarted Aug 2020

Aurora, Colorado, United States • Las Vegas, Nevada, United States • Nashville, Tennessee, United States +2 more locations

COMPLETEDPhase 3< 1 mile

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606

This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Aviptadil plus current standard of care (SOC), or with placebo plus current SOC.

Covid19

National Institute of Allergy and Infectious Diseases (NIAID)471 participantsStarted Apr 2021

Tucson, Arizona, United States • Fresno, California, United States • Loma Linda, California, United States +37 more locations

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Find Trials by Condition in Dallas

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

The Periviable GOALS Decision Support Tool

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma